DelveInsight’s ‘Acute Myeloid Leukemia Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Acute Myeloid Leukemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acute Myeloid Leukemia pipeline domain.
For Acute Myeloid Leukemia emerging drugs, the Acute Myeloid Leukemia pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Acute Myeloid Leukemia Pipeline Report
- DelveInsight’s Acute Myeloid Leukemia Pipeline analysis depicts a robust space with 260+ active players working to develop 260+ pipeline therapies for Acute Myeloid Leukemia treatment.
- The leading Acute Myeloid Leukemia companies include GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others are evaluating their lead assets to improve the Acute Myeloid Leukemia treatment landscape.
- Key Acute Myeloid Leukemia pipeline therapies in various stages of development include Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others.
- In March 2023, the FDA granted orphan drug designation to EP0042 for use as a potential therapeutic option in patients with acute myeloid leukemia (AML) who have acquired resistance to FLT3 inhibitors, according to an announcement from Ellipses Pharma.
- In March 2023, Immune-Onc Therapeutics, Inc., a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced that data from Phase 1 dose escalation for IO-108, a novel myeloid checkpoint inhibitor targeting Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2, also known as ILT4), has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 14 – 19, 2023 in Orlando, Florida.
- In March 2023, Jazz Pharmaceuticals plc announced that Vyxeos (daunorubicin and cytarabine liposome for injection) had been added to the drug formularies of eight additional provinces, including British Columbia, Ontario, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Alberta, and Newfoundland and Labrador.
- In January 2023, Innate Pharma SA announced the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123.
- In January 2023, the FDA granted JBI-802 orphan drug designation for patients diagnosed with small cell lung cancer (SCLC) and acute myeloid leukemia (AML), according to a press release from Jubilant Therapeutics.
- In August 2022, Foghorn® Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) had placed a full clinical hold on the Phase 1 dose escalation study of FHD-286, an inhibitor of BRG1/BRM, in relapsed and refractory acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). The dose escalation Phase 1 study of FHD-286 in metastatic uveal melanoma (mUM) continues per protocol. The company plans to report data from the mUM study in the first half of 2023.
- In May 2022, Aptose Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. Currently, an international Phase 1/2 clinical trial is ongoing for HM43239 in the R/R AML patient population. HM43239 received orphan drug designation from the FDA for the treatment of acute myeloid leukemia in 2018.
- In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) had granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).
Request a sample and discover the recent breakthroughs happening in the Acute Myeloid Leukemia pipeline landscape @ Acute Myeloid Leukemia Pipeline Outlook
Acute Myeloid Leukemia Overview
Acute myeloid leukemia (AML) is the most common type of leukemia in adults, accounting for roughly 80% of all cases. Clonal expansion of immature “blast cells” in the peripheral blood and bone marrow results in ineffective erythropoiesis and bone marrow failure. Cure rates have increased up to 15% in patients over the age of 60, and around 40% in patients under the age of 60, thanks to recent advancements in management guidelines. Leukemias are clonal diseases, which means that cancer develops from a mutation in a single original cell. This happens in a hematopoietic stem cell, specifically a myeloblast, in AML. A myeloblast is a bone marrow precursor cell that is immature. This means a myeloblast will mature (or differentiate) into a healthy white blood cell known as an agranulocyte or a monocyte. Myeloblasts do not mature in AML and grow and multiply uncontrollably. Myeloblasts cannot perform the normal functions of mature blood cells because they are immature cells.
Find out more about Acute Myeloid Leukemia medication @ New Drug for Acute Myeloid Leukemia
Acute Myeloid Leukemia Pipeline Analysis: Drug Profile
Omidubicel: Gamida Cell
Omidubicel is an advance cell therapy being researched as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Omidubicel is the first bone marrow transplant product to be designated as a Breakthrough Therapy by the US Food and Drug Administration, and it has also been designated as an Orphan Drug in the US and the EU.
Uproleselan: GlycoMimetics
Uproleselan (GMI-1271) is a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment by blocking E-selectin (an adhesion molecule on cells in the bone marrow). Preclinical research suggests that the drug may play a role in removing cancerous cells from the bone marrow’s protective environment, where they hide and escape the effects of chemotherapy. GMI-1271 was also associated with a reduction in chemotherapy-induced neutropenia and chemotherapy-induced mucositis in preclinical studies using animal models of AML, the results of which were presented at meetings of the American Society of Hematology (ASH). The drug is currently in Phase III clinical trials for the treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Acute Myeloid Leukemia Pipeline Therapies and Key Companies
- Omidubicel: Gamida Cell
- Uproleselan: GlycoMimetics
- ALT 803: ImmunityBio
- BPX-501: Bellicum Pharmaceuticals
- ALLO-316: Allogene therapeutics
- ALL0-819: Allogene therapeutics
- JNJ 63709178: Janssen Research & Development, LLC
- IO 202: Innovation Limited
- JSP 191: Jasper Therapeutics
Learn more about the novel and emerging Acute Myeloid Leukemia pipeline therapies @ Acute Myeloid Leukemia Clinical Trials
Acute Myeloid Leukemia Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Intravenous
- Subcutaneous
- By Molecule Type
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Scope of the Acute Myeloid Leukemia Pipeline Report
- Coverage: Global
- Key Acute Myeloid Leukemia Companies: GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellicum Pharmaceuticals, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, and others.
- Key Acute Myeloid Leukemia Pipeline Therapies: Uproleselan, SKLB1028, Pevonedistat, Orca T, Magrolimab, Iomab-B, Entospletinib, Nivolumab, ALT 803, BPX-501, TCB008, Tamibarotene, Pyronaridine, Trisenox (Arsenic Trioxide), NEI-01, MDG1011, OmnImmune, anti-FLT3 CAR-T, JNJ 63709178, IO 202, IDH 305, JSP 191, AB001, P-ckit-ALLO1, MP-0533, ALLO-316, ALL0-819, and others.
Dive deep into rich insights for drugs used for Acute Myeloid Leukemia treatment; visit @ Acute Myeloid Leukemia Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Acute Myeloid Leukemia Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Acute Myeloid Leukemia Pipeline Therapeutics |
| 6. | Acute Myeloid Leukemia Pipeline: Late Stage Products (Phase III) |
| 7. | Acute Myeloid Leukemia Pipeline: Late Stage Products (Phase III) |
| 8. | Acute Myeloid Leukemia Pipeline: Mid Stage Products (Phase II) |
| 9. | Acute Myeloid Leukemia Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Acute Myeloid Leukemia therapy in the pipeline, reach out @ Acute Myeloid Leukemia Medication
Related Reports
Acute Myeloid Leukemia Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute myeloid leukemia companies, including Takeda Oncology, Immunity Bio, Teva Pharmaceuticals, among others.
Relapsed/Refractory Acute Myeloid Leukemia Epidemiology
Relapsed/Refractory Acute Myeloid Leukemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted relapsed/refractory acute myeloid leukemia epidemiology in the 7MM.
Acute Lymphocytic Leukemia Pipeline
Acute Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute lymphocytic leukemia companies, including AbbVie, Novartis, Jazz Pharmaceutical, among others.
Chronic Lymphocytic Leukemia Pipeline
Chronic Lymphocytic Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic lymphocytic leukemia companies, including Celgene, Loxo Oncology, Octapharma, among others.
Chronic Myeloid Leukemia Pipeline
Chronic Myeloid Leukemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic myeloid leukemia companies, including Kartos Therapeutics, Novartis, Incyte Corporation, among others.
Other Trending Reports
Goitre Market | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Blogs
Related Cases Studies
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187